The Effect Of Large Strains Of Rhodiola Roseea Injection On The Immune Function Of Patients With Ovarian Cancer

Objective(1) To analyze the changes of peripheral blood cell immune function and CD4+CD25+ regulatory T cells, the inflammation factor IL-10, TGF-β1 coming from the secretion of Tregs cells and study the correlation of the indexes and clinical tumor staging in patients with ovarian cancer in different clinical stages.(2) To observe the influence on immune function with large strains of rhodiola roseea injection therapy in patients with ovarian cancer.Methods(1) Study group:ninety cases patients with ovarian cancer in obstetrics and gynecology department in Puyang City People’s hospital from 2013 December to 2014 December. According to the FIGO clinical staging criteria, The patients were divided into three group, Ⅰ～Ⅱstage group, Ⅲstage group, IVstage group.(2) Detection method:in the morning on the date of detection, the fasting peripheral blood was respectively taken for measurement on the twenty-forth hour, after the onset with flow cytometry assay to detect the peripheral blood T cell subsets:CD3+T cells, CD4+ T cells, the radio of CD4+/CD8+T cells, NK cells for peripheral blood lymphocyte and the percentage of CD4+CD25+ regulatory T lymphocyte. To observe the percentage of transforming growth factor-β1(TGF-β1) and interleukin-10 (IL-10) positive cells coming from regulatory T cells and compare the levels of the above indexes among different groups.Results(1) There were significant differences in the proportion of T lymphocyte subsets in the peripheral blood of ovarian cancer patients with different stages. Among them, the percentage of CD3+ T cells, CD4+ T cells,NK cells accounted for peripheral blood lymphocyte and the radio of CD4+/CD8+ T cells were not statistically significant between I ～Ⅱ stage group and Ⅲ stage group (P>0.05), but the percentage of CD3+ T cells, CD4+T cells, NK cells accounted for peripheral blood lymphocyte and the radio of CD4+/CD8+ T cells had statistically significant difference between IV stage group and III stage group (P <0.05).(2) The percentage of CD4+CD25+regulatory T lymphocyte, transforming growth factor-β1 (TGF-β1) and interleukin-10 (IL-10) positive cells coming from regulatory T cells accounted for peripheral blood lymphocyte had statistically significant difference among three groups(P<0.05).(3) After large strains of Rhodiola roseea injection therapy, the percentage of CD4+CD25+ regulatory T lymphocyte, CD4+CD25+FOXp3+regulatory T lymphocyte, transforming growth factor-β1(TGF-β1) and interleukin-10 (IL-10) positive cells coming from regulatory T cells accounted for peripheral blood lymphocyte in the treatment group were lower than before, the difference are statistically significant (P< 0.05).Meanwhile, the percentage of CD4+CD25+ regulatory T lymphocyte, CD4+CD25+FOXp3+ regulatory T lymphocyte, transforming growth factor-β1(TGF-β1) and interleukin-10 (IL-10) positive cells coming from regulatory T cells accounted for peripheral blood lymphocyte in the control group rose slightly than before, but the difference are not statistically significant(P >0.05). After treatment, the difference between the two groups are statistically significant (P<0.05).ConclusionThere are differences in the immune function of ovarian cancer patients in different clinical stages. Early T cell immune function changes are reflected in the increasing of the proportion in T cell subsets, With the progress of clinical stages, the percentage of T cell subsets increase further. The immune function of the body is mainly expressed by immunosuppression of cells. In the later period, it is reflected that the number of T cells decreased. The large strains of Rhodiola roseea injection therapy can decrease peripheral blood regulatory T cells, reduce the cellular immune inhibition, regulate the early immune imbalance and improve the body immunity in patients with ovarian cancer.